INVITED REVIEW

Medical and surgical management of perianal Crohn’s disease

Samuel O. Adegbola\textsuperscript{a,b}, Anthea Pisani\textsuperscript{c}, Kapil Sahnan\textsuperscript{a,b}, Phil Tozer\textsuperscript{a,b}, Pierre Ellul\textsuperscript{c}, Janindra Warusavitarne\textsuperscript{a,b}

St. Mark’s Hospital, Harrow, UK; Imperial College, London, UK; Mater dei Hospital, Malta

Abstract

Crohn’s disease is increasingly thought to encompass multiple possible phenotypes. Perianal manifestations account for one such phenotype and represent an independent disease modifier. In its more severe form, perianal Crohn’s disease confers a higher risk of a severe and disabling disease course, relapses, hospital admissions and operations. This, in turn, imposes a considerable burden and disability on patients. Identification of the precise manifestation is important, as management is nuanced, with both medical and surgical components, and is best undertaken in a multidisciplinary setting for both diagnosis and ongoing treatment. The introduction of biologic medication has heralded a significant addition to the management of fistulizing perianal Crohn’s disease in particular, albeit with modest results. It remains a very challenging condition to treat and further work is required to optimize management in this group of patients.

Keywords Crohn’s disease, perianal, surgery, medical therapy

Ann Gastroenterol 2018; 31 (1): 1-11

Introduction

Crohn’s disease (CD) affects approximately 145 people per 100,000 population in the UK and between 4 and 250 people per 100,000 population worldwide, having a varied presentation [1]. Perianal CD (PCD) represents one phenotype [2] and is an independent disease modifier [3]. PCD encompasses a range of manifestations, from skin tags, to fissures, ulcers, strictures, abscesses, and fistulas. Various attempts have been made to classify these manifestations [4,5], but the uptake of these has been poor to date, possibly because of their limited clinical applicability and prognostic relevance, especially in relation to treatment [6]. In 2003, the American Gastroenterological Association (AGA) clinical practice committee adopted a pragmatic approach, classifying perianal lesions based on broad groupings of fistulizing manifestations (perianal and rectovaginal fistula/abscess) and non-fistulizing manifestations (skin tags, fissures, ulcers, anorectal stricture, hemorrhoids, anal cancer) [7].

The true incidence of PCD is difficult to determine given the heterogeneity in definition and reporting [8]. A wide range of prevalence is reported [9] and accuracy is further hampered by the variable data sources (including single-center experiences and small population studies). Perianal fistulas account for a particularly disabling disease phenotype and occur in approximately a third of patients with CD [7,10,11]. The management of PCD is multidisciplinary and in this review we describe evidence-based surgical and medical aspects of treatment.

Non-fistulizing manifestations

The majority of studies of PCD focus on fistulas, whilst non-fistulizing disease is less well studied. Non-fistulizing manifestations can account for considerable morbidity if undiagnosed and untreated.

Anal fissures

The reported prevalence of anal fissures varies between 10-59% [12-15]. They can occur in any position, whereas in the absence of CD they are usually found in the midline, posteriorly [15,16]. Often painless, they can however, still present with pain and bleeding. The etiology is thought to be inflammatory rather than due to the high anal tone/ischemia seen in non-CD fissures.

Fifty percent of fissures could heal spontaneously with treatment of the underlying CD [17]. In those that persist,
topical therapy (glyceryl trinitrate/diltiazem ointment) can sometimes be effective in improving symptoms [14,17], although this is paradoxical from an etiological point of view. Other treatments include steroids, antibiotics and aminosalicylates, and retrospective studies suggest that about half of patients show some response to these [18]. Anti-tumor necrosis factor (TNF)-α therapy has also been used in the management of fissures. Bouguen et al [19] retrospectively reviewed the records of treated cases across two tertiary referral centers, reporting that 70% (24/34) of fissures treated with infliximab healed over a median follow up of 3 years. Surgical options described for medically refractory fissures include lateral internal sphincterotomy, fissurectomy or advancement flap closure. Sphincterotomy carries a risk of minor incontinence in patients without chronic, diarrhea-causing inflammatory bowel disease (IBD). Given that sphincter tone is not the presumed mechanism, it is not recommended in CD, although there have been reported successes in small numbers [13]. The authors do not advocate this approach.

Anal ulceration

Anal ulceration is thought to be common in the context of PCD (Fig. 1A,B). A retrospective review by Bouguen et al [19] reported that 94 of 99 patients with non-fistulizing PCD treated with infliximab infusions had ulceration. Siproudhis et al [17] report a prevalence of 67% (43/64) in consecutive CD patients with anal lesions referred to a tertiary institution. Other studies have reported lower rates [8,20], perhaps reflecting case mix or differences in classification, as some confuse superficial fissures with cavitating ulcers [5]. Anal ulceration is often associated with proctitis [17] and can present with pain, pruritus, discharge and bleeding [19]. Management options include topical treatments such as metronidazole for short-term improvement of symptoms [21], and topical tacrolimus, which has been shown to improve ulcer depth, surface area and appearance in the short term [22]. Infliximab is also beneficial, with up to 83% complete resolution at long-term follow up [19,23]. Ouraghi et al reported short-term (<6 months) response rates in in 63% (10/16) of patients with fissures/ulcers, with significant relapse rates (61%) at 1 year. Bouguen et al reported complete response in 72% of patients at 3 years [19].

Anal stenosis / stricture

Strictures may follow ulceration, often in the presence of proctitis [24]. Symptoms include bloody diarrhea, constipation, perianal pain, and incontinence [24]. Examination under anesthetic and imaging allow assessment of the stricture, whilst biopsies should be taken to exclude malignancy.

Treatment options include dilatation using Hegar dilators, reported to lower the likelihood of fecal diversion [25]. Following initial dilatation under general anesthetic, patients can continue self-dilation at home. Treatment with anti-TNF therapy has been reported to be successful. Bouguen et al [19] report complete regression of strictures in 55% of cases (12/22) at 3-year follow up following infliximab treatment. Infliximab was concomitant with anal dilatation in half those with complete regression. Plastic surgical techniques may also be considered, but the risk of wound breakdown warrants caution, especially in the presence of proctitis.

A retrospective review of the natural history of 102 patients with CD-related anorectal strictures reported 59% (52/88) healing after a median follow up of 2.8 years with multimodal treatment [26]. Strictures are associated with an increased likelihood of fecal diversion. Galandiuk et al [25] prospectively analyzed consecutive patients (n=86) undergoing treatment for PCD. They demonstrated that anal strictures were associated with an increased risk of permanent stoma on univariate analysis (odds ratio [OR] 3.0, 95% confidence interval [CI] 1.22-7.67; P=0.02) and multivariate analysis (OR 3.69, 95%CI 1.39-10.7; P=0.01). The presence of colonic disease in association with anal canal strictureing showed a fivefold risk of permanent stoma on multivariate analysis (OR 5.73, 95% CI 1.49-27.0; P=0.016).

Skin tags and hemorrhoids

Skin tags are a common manifestation of PCD [27,28] (Fig. 2). The “large edematous type” are thought to arise secondary to lymphatic obstruction [5]. They are hard and cyanotic, usually coexistent with fissures and often symptomatic (pain/discomfort). The “elephant ears” type are flat, soft and usually asymptomatic. Excision may be sought to ameliorate symptoms, but it is important to discuss the risks of impaired

---

**Figure 1** (A and B) small and massive anal ulceration in patients with perianal crohn’s disease
wound healing or perianal ulceration [29]. Limited rather than extensive excision may reduce the risk of subsequent stenosis.

Symptomatic hemorrhoids are thought to be relatively uncommon in CD patients compared with the general population [14]. Data on surgical treatment are sparse with poorly measured outcomes, making assessment difficult [14,30,31]. In general, surgical treatment is rarely required.

**Anal cancer**

The incidence of anal cancer is not known but it is thought to be rare [32]. There are reports of an association between complicated PCD and cancer in the anorectum [32-35]. Diagnosis is often delayed because of the distorted anatomy in longstanding PCD. A heightened suspicion is often required in the context of prolonged perianal disease and a low threshold for clinical evaluation and biopsies should be adopted. Management is the same as for anal malignancy of non-IBD origin; however, the risks of wound-related complications are higher in CD.

**Fistulizing manifestations – perianal fistula and abscess**

Multidisciplinary management of PCD is strongly advised as gold-standard care [36]. Active luminal disease should be treated with the aim of inducing and maintaining remission [37]. Prior to the use of immunosuppressive medications any perianal sepsis needs to be drained. Steroids should be avoided as they do not have a role in management [38].

**Medical management**

**Antibiotics (ciprofloxacin/metronidazole)**

In a systematic review of randomized controlled trials (RCTs) on the use of antibiotics in IBD, three trials evaluated perianal fistulas and showed a significant reduction in fistula drainage (relative risk 0.8, 95%CI 0.66-0.98) with no heterogeneity (I²=0%) [40]. Usual dosages of metronidazole are 20 mg/kg/day or 750-1000 mg/day divided into 3 or 4 doses, whilst the dosage of ciprofloxacin is 1000-1500 mg/day divided into 2 doses. In most studies therapy lasted for 8-12 weeks. Long-term use is limited by side-effects and drug resistance [38,39]. However, antibiotics rarely lead to complete or sustained healing and symptoms recur on cessation [37].

**Immunomodulatory treatment**

**Thiopurines.** Perianal fistula (Fig. 2) at diagnosis is considered a poor prognostic marker and patients may benefit most from early introduction of immunomodulators or biological therapy [37]. Azathioprine and 6-mercaptopurine are antimetabolite agents with immunosuppressive properties that have been shown to be effective in the management of luminal CD [40].

In a meta-analysis of five RCTs carried out in 1995, perianal fistula response was assessed as a secondary endpoint and was seen in 54% (22/49) compared to 21% (6/29) in the placebo group (pooled OR 4.44, 95%CI 1.50-13.2) [41]. Fistula response was defined as complete healing or decreased discharge, using 2-3 mg/kg azathioprine or 1.5 mg/kg 6-mercaptopurine. These immunomodulators may not produce a response for three months (or longer) with implications for acute management [42].

**Calcineurin inhibitors.** A study by Sandborn et al. [43] demonstrated that tacrolimus (0.2 mg/kg/day) was effective in improving symptoms (43% vs. 8%, P<0.05), but not fistula closure (P=0.86). A more recent study evaluated the role of tacrolimus in patients with severe CD intolerant or unresponsive to anti-TNF agents.

In a retrospective study, intravenous cyclosporine followed by oral cyclosporine achieved complete closure in about 33% of patients, but the response was lost after discontinuation [44]. The limited data on intravenous cyclosporine in PCD come from uncontrolled case series including fewer than 100 patients [37]. Its place in the management of PCD is unclear.

**Anti-TNF-α therapy.** Infliximab, adalimumab, and certolizumab have been shown to be effective as both induction and maintenance therapy in moderate to severe CD, including patients with fistulas. A meta-analysis performed by Kawalec et al. [45] included 19 clinical trials, of which seven evaluated anti-TNF agents for the treatment of fistulizing CD, though only two of these trials were designed specifically to address this issue. During induction and maintenance, significantly more patients achieved a ≥50% reduction in draining fistulas (clinical response) versus placebo (relative benefit [RB] 1.70, P=0.04, and RB 1.84, P=0.001, respectively) and complete fistula closure (clinical remission) (RB 2.44, P=0.02, and RB 2.03, P=0.0003) [45]. Fistula outcomes in trials of medical treatment have mainly used clinical assessment to determine response and remission. Assessment with magnetic resonance imaging (MRI) has demonstrated that deep fistula healing lags behind clinical remission by a year [46].
Several combination regimens to be effective in the treatment of perianal fistulas [58-61]. infliximab-naïve and treated patients have shown adalimumab last visit dates ranging from just 4 to 36 weeks) was achieved adalimumab. Complete fistula healing by date of last visit (with previously failed to respond to infliximab and were prescribed 13%, $P<0.02$). The CHOICE trial assessed patients who had the fistula closure was 33% in the adalimumab group (controls with adalimumab for 26 weeks had fistula closure compared to CHARM trial, 30% of patients with perianal fistulas treated did not show superiority of adalimumab to placebo. In the closure from the CLASSIC-1 trial [54] and the GAIN study [55]. Improvement was a secondary endpoint. Initial data on fistula is derived mainly from studies where fistula closure or antibody. The data on the effect of adalimumab on PCD

Adalimumab

Adalimumab is a fully human, anti-TNF monoclonal antibody. The data on the effect of adalimumab on PCD is derived mainly from studies where fistula closure or improvement was a secondary endpoint. Initial data on fistula closure from the CLASSIC-1 trial [54] and the GAIN study [55] did not show superiority of adalimumab to placebo. In the CHARM trial, 30% of patients with perianal fistulas treated with adalimumab for 26 weeks had closure compared to the closure rate of 13% with placebo ($P<0.04$) [56]. By week 56 the fistula closure was 33% in the adalimumab group (controls 13%, $P<0.02$). The CHOICE trial assessed patients who had previously failed to respond to infliximab and were prescribed adalimumab. Complete fistula healing by date of last visit (with last visit dates ranging from just 4 to 36 weeks) was achieved in 40% [57]. A number of retrospective studies in both infliximab-naïve and treated patients have shown adalimumab to be effective in the treatment of perianal fistulas [58-61].

Infliximab

The first anti-TNF-α agent shown to be effective in an RCT for inducing and maintaining closure of perianal fistulas was infliximab, an IgG1 murine-human chimeric monoclonal antibody. In the trial, 68% of patients with perianal fistulas who received the 5 mg/kg dose had a clinical response, compared with 26% receiving placebo ($P=0.002$). Fistula closure was observed in 55% of patients versus 13% in the placebo group ($P=0.001$). The median length of time to response was 2 weeks and fistulas remained closed for approximately 3 months [47]. The ACCENT II trial, a multicenter, double-blind, randomized, placebo-controlled trial evaluating the efficacy of maintenance infliximab, confirmed the initial response and showed that, after 54 weeks of therapy, 46% of patients in the infliximab arm had a sustained response versus 23% in the placebo arm ($P=0.001$) [48]. ACCENT II also demonstrated that infliximab significantly reduced hospitalizations and surgery in this group of patients [49]. Despite these favorable results, abscess development was observed in 10-15% of cases, most likely secondary to external fistula closure. Nevertheless, it is unclear whether this rate is higher than the spontaneous rate of abscess formation in patients with fistulas [50]. Further data from ACCENT II concluded that abscess formation was not dependent on cumulative infliximab exposure [51]. A retrospective study showed that about two thirds of patients treated with infliximab for fistulizing PCD for a median of 250 weeks experienced fistula closure, though one third of patients had fistula recurrence after initial fistula closure. The study also revealed that, in addition to long-term infliximab, combination therapy with thiopurines was associated with better outcomes [52]. A recent cross-sectional study demonstrated that achieving serum infliximab drug levels of more than ≥10.1 μg/mL in patients with perianal fistulas improved outcomes [53]. This might form part of a treat-to-target strategy.

Combination therapies. Several combination regimens have been explored. A double-blind placebo-controlled study found that a combination of ciprofloxacin and infliximab improved Perianal Disease Activity Index compared to infliximab alone. However, the 73% clinical response in the combination treatment group (vs. 39% in the placebo and infliximab group) was not statistically significant ($P=0.12$) [66]. Combination ciprofloxacin and adalimumab treatment has also demonstrated benefit, with a clinical response in 71% of patients in the combined treatment group versus 47% in the adalimumab alone group ($P=0.047$). Combination treatment was associated with a greater change in mean CDAI and mean IBD Questionnaire score at week 12 ($P=0.005$ and $P=0.009$, respectively). In the latter study, the difference between the two groups with regards to fistula closure rate was not maintained 12 weeks after discontinuation of the antibiotic therapy ($P=0.22$) [67].

Combination of anti-TNF therapy with immunomodulators (e.g., thiopurines) has been assessed. Combination with an immunomodulator has the additional potential beneficial effects of decreasing anti-drug antibody formation as well as risk of drug clearance for all anti-TNF agents [68]. A meta-analysis in 2015, pooling data from 11 RCTs, demonstrated no apparent benefit from combination therapy as regards partial (OR 1.25, 95%CI 0.84-1.88) or complete fistula closure (OR 1.1, 95%CI 0.68-1.78) [69].

Current guidance suggests a combination therapy of ciprofloxacin and anti-TNF. Thiopurines may be added to enhance the effect of anti-TNF [37].

Certolizumab pegol

Certolizumab pegol is a humanized, PEGylated, Fc-free anti-TNF monoclonal antibody. It has been evaluated in perianal fistulizing CD by way of randomized double-blind controlled trials in the PRECiSE studies [62-64]. Responders (≥100-point decrease from baseline CD Activity Index [CDAI]) with draining fistulas following induction treatment with certolizumab were randomized to certolizumab pegol 400 mg (n=28) or placebo (n=30) as maintenance therapy with assessment at week 26. Most had perianal fistulas (55/58). Fifteen of the 28 patients (54%) had protocol-defined fistula closure (≥50% closure at two consecutive post-baseline visits ≥3 weeks apart) compared with 13/30 (43%) in the placebo group. This result was not statistically significant ($P=0.069$). Interestingly, it was noted that a subgroup analysis of an altered definition of fistula closure, i.e., "those patients with 100% fistula closure", demonstrated a significant difference between certolizumab and placebo (36% vs. 17%, $P=0.038$) [65].

Infliximab

Infliximab is an α4β7 integrin monoclonal antibody, demonstrated a higher rate of fistula closure than placebo (41.2% vs. 11%, $P=0.03$) [70]. In addition, the maintenance intention-to-treat population with fistulizing disease was analyzed. Some 28% of patients given vedolizumab as sole treatment maintained fistula closure at one year versus 11% of those who received placebo maintenance [71]. In view of the small numbers, no

Certolizumab pegol

Certolizumab pegol is a humanized, PEGylated, Fc-free anti-TNF monoclonal antibody. It has been evaluated in perianal fistulizing CD by way of randomized double-blind controlled trials in the PRECiSE studies [62-64]. Responders (≥100-point decrease from baseline CD Activity Index [CDAI]) with draining fistulas following induction treatment with certolizumab were randomized to certolizumab pegol 400 mg (n=28) or placebo (n=30) as maintenance therapy with assessment at week 26. Most had perianal fistulas (55/58). Fifteen of the 28 patients (54%) had protocol-defined fistula closure (≥50% closure at two consecutive post-baseline visits ≥3 weeks apart) compared with 13/30 (43%) in the placebo group. This result was not statistically significant ($P=0.069$). Interestingly, it was noted that a subgroup analysis of an altered definition of fistula closure, i.e., "those patients with 100% fistula closure", demonstrated a significant difference between certolizumab and placebo (36% vs. 17%, $P=0.038$) [65].

Current guidance suggests a combination therapy of ciprofloxacin and anti-TNF. Thiopurines may be added to enhance the effect of anti-TNF [37].

Vedolizumab. There are limited data on the role and efficacy of vedolizumab in PCD. In the GEMINI II trial, vedolizumab, an α4β7 integrin monoclonal antibody, demonstrated a higher rate of fistula closure than placebo (41.2% vs. 11%, $P=0.03$) [70]. In addition, the maintenance intention-to-treat population with fistulizing disease was analyzed. Some 28% of patients given vedolizumab as sole treatment maintained fistula closure at one year versus 11% of those who received placebo maintenance [71]. In view of the small numbers, no
Management of perianal Crohn’s disease

Definitive recommendation can be made regarding the use of vedolizumab in PCD.

**Ustekinumab.** Ustekinumab is active against the p40 subunit of interleukin-12 and interleukin-23. Its role in perianal fistulizing disease has been evaluated in small studies. In a retrospective analysis of 45 CD patients with perianal fistulas, 31.1% (n=14) achieved complete healing as demonstrated by pelvic MRI or dedicated pelvic contrast-enhanced ultrasound [72]. In patients with anti-TNF refractory disease, Battat et al [51] reported that at ≥6 months 4/6 patients had a >50% reduction from baseline in the number of draining fistulas, with 2/6 patients having closure of all fistulas. In a similar study [73], perianal disease improved (on the basis of physician judgment) in 11 of 18 (61%) patients with active perianal fistulas. Larger studies are required to define ustekinumab’s role in perianal Crohn’s fistula treatment.

**Other options.** Other drugs, such as mycophenolate mofetil, methotrexate and thalidomide, are not currently recommended for standard routine clinical practice [74]. Exclusive enteral nutrition (EEN) is an established treatment option in children with CD [75]. A case series that included three children with perianal disease at diagnosis showed that EEN, together with surgery and antibiotics, was effective in inducing disease remission and assisted in the healing of the perianal disease [76]. Its role in the adult population with PCD has not been studied.

**Surgical management**

The fistula anatomy, disease activity and presence of complicating features (proctitis, abscess) influence surgical options. The AGA [7] empirically distinguishes fistulas as simple or complex, with the former having higher rates of healing. Simple fistulas are classified as superficial or low intersphincteric/transsphincteric with a single external opening, no pain or fluctuation to suggest perianal abscess, no evidence of a rectovaginal fistula, and no evidence of anorectal stricture. Complex fistulas (Fig. 2A,B), in contrast, are high fistulas (intersphincteric / transphincteric / extrasphincteric / suprasphincteric) and may be associated with multiple external openings, presence of pain or fluctuation to suggest a perianal abscess, presence of a rectovaginal fistula, presence of an anorectal stricture, or presence of active rectal disease at endoscopy [7].

Management of fistulizing PCD has evolved from a focus on definitive surgical repair to multidisciplinary management, with surgical drainage in preparation for medical treatment. In many circumstances surgery can be a good adjunct to symptom palliation. Diversion or ablation are offered in the case of failure.

**Examination under anesthesia (EUA) with drainage of collections / seton insertion**

EUA and drainage is the first-line treatment for acute abscess so as to control local sepsis prior to initiating medical treatment [36]. Loose setons maintain patency of fistula tracts, limiting recurrent abscess formation [77, 78]. When the goal of medical treatment is fistula closure, the seton must be removed, often towards the end of anti-TNF treatment induction [77], although the optimal timing of removal is unknown. Loose setons may be left in situ permanently to control local sepsis and reduce symptoms, although on occasion they may need to be replaced. Loose setons also serve as a bridge between optimization of medical therapy and definitive surgical treatment. Cutting setons, by contrast, are a method of fistulotomy and risk sphincter injury and the authors do not advocate this in perianal Crohn’s fistula [6, 77].

**Definitive surgical options / curative procedures**

**Advancement flaps.** Advancement flaps involve raising a flap of tissue adjacent to the internal opening of a fistula, excising the internal opening and securing the flap to cover it [79]. This approach aims to close the high-pressure end of the fistula and disconnect the tract from the gut [80]. Several small studies have reported on variations of advancement flaps, with healing rates varying from 40–80% [80–82] and incontinence rates of approximately 9%, usually from flaps involving the internal sphincter [82]. Flap procedures avoid external wounds, which can be associated with impaired healing and perineal scarring [6]. The procedure is thought to be easier in patients with perineal descent and internal intussusception [6]. Relative contraindications include proctitis, cavitating ulceration and anal stenosis [83]. The evidence to support routine use in CD is limited.

**In-fill materials (fibrin glue, fistula plug).** These techniques have the benefit of having no impact on the sphincter mechanism and can be repeated in the presence of recurrence. Fibrin glue aims to seal the tract by activating thrombin to form a fibrin clot [84, 85]. This clot may facilitate the wound healing process, although evidence for this is lacking. Success rates are very variable (0–100%) [86], reflecting small numbers, varying techniques and limited follow up in the studies published. A review in 2009 reported a 35% (13/37) healing rate in six studies [86] and an RCT in 2010 had a 20% (11/54) remission rate for patients with CD (at median follow up of 37 months) [6, 87]. Longer-term healing rates are lacking.

Anal fistula plugs are bioprosthesis devices thought to promote wound healing [88]. They elicit no foreign body or inflammatory reaction and provide a collagen scaffold populated by a patient’s endogenous cells over approximately three months [89, 90]. As with glue, the evidence is heterogeneous, lacking robust methodology, with widely variable healing as a result of the small numbers of CD patients studied (15–100%) [82, 91–93]. A systematic review in 2012 reported the pooled proportion of patients achieving closure with a fistula plug in 42 patients with CD was 55% (95%CI 0.39-0.70) [91].

Despite poor primary healing, in-fill materials may serve as scaffolds for delivering stem cells and local pharmaceuticals [94]. A phase II multicenter study of complex...
fistula (14 of 49 patients had PCD) compared glue vs. glue plus expanded adipose-derived stem cells (ASCs) with healing in 16% vs. 71% respectively [94].

**Stem cell therapy.** Adult mesenchymal stem cells (MSCs), including ASCs, are a promising tool for treating inflammatory and autoimmune diseases because of their immunomodulatory capacity and paracrine effects through trophic factors with antifibrotic, anti-apoptotic, or pro-angiogenic properties [95,96]. Stem cell therapy mainly transplants autologous or allogeneic stem cells into patients. Several trials have demonstrated the safety and efficacy of local administration of MSCs into the Crohn's perineal fistulas [97-103]. These have so far demonstrated that the technique is safe and initial studies have impressive healing rates. Recently, the results of a phase III RCT investigating the efficacy of allogeneic ASCs for the treatment of PCD were reported. Among 212 patients randomized, 107 patients received a single injection of 120 × 10⁶ MSCs and 105 received placebo. At 24 weeks, the MSC-treated patients had significantly higher rates of combined remission, defined as closure of the external fistula tract and absence of fluid collections >2 cm on MRI; 50% (53/107) healed in the MSC group compared with 34% (36/105) in the placebo group (P=0.024). This beneficial effect was maintained at week 52 (56.3% vs. 38.6%, respectively, P=0.01) [103]. Additionally, MSC-treated patients had a significantly shorter time to clinical remission (6.7 vs. 14.6 weeks). The higher than expected success rate in the placebo arm was thought to be attributable to the fact that all patients underwent fistula curettage, surgical drainage, and closure of the internal orifice, which can result in healing irrespective of MSC delivery [104]. An alternate explanation could be the low threshold for defining clinical and radiological remission. The absence of collections >2 cm in at least 2 of 3 dimensions means that a significant volume of undrained sepsis may still have been present and yet described as remission. Despite this, almost all patients enrolled in trials for stem cells were refractory to standard therapy and, regardless of the origin of the MSCs, or the dose and method of administration, results have largely suggested superior efficacy compared with conventional therapy in a difficult-to-treat subgroup [104].

A systematic review and meta-analysis including 14 studies (n=477) [105], revealed that MSCs had significantly better efficacy compared with other treatments (risk difference 0.21, P=0.0004). The review also showed that, after MSC treatment, the group with a higher baseline CDAI had a higher healing rate and clinical response compared to the group with a lower CDAI (79.17 vs. 47.53, P=0.011). A moderate dose of 2-4 × 10⁶ cells/mL had a higher healing rate and a lower recurrence rate compared to other dosages, whilst adipose-derived MSCs had an advantage over bone marrow-derived MSCs [105]. Follow up is generally short. The longest follow up comes from a group where 10 patients were followed up for 6 years after autologous bone marrow-derived MSCs. The cumulative probabilities of surgery- and medical-free survival were 100% and 88% at 1 year and 63% and 25% at 6 years, with no adverse events being recorded [106].

Stem cell treatment appears to be safe and, whether alone or in combination with other modalities, may generate improved healing and symptomatic relief. Despite the promising results, the ideal type of MSC, appropriate dosage, uniform protocol for cell isolation and the number of injections still require clarification [107].

**Other techniques: ligation of intersphincteric fistula tract (LIFT), over-the-scope clip (OTSC), fistula tract laser closure (FiLaC), video-assisted anal fistula treatment (VAAFT)**

LIFT procedure involves ligation and excision of the fistula tract in the intersphincteric space. Two studies have published results from Crohn's perianal fistulas. Gingold et al reported their experience in a small series of 15 patients. There was 67% (8/12) success (clinical healing) at 12 months with no reports of incontinence [6,108]. A more recent retrospective single-center study by Kaminsky et al [109] reported healing in 75% (6/8) at <12 months follow up and 33% (5/15) in patients with follow up of more than one year.

Other emerging sphincter sparing procedures include VAAFT [110,111], FiLaC [112,113], and OTSC [114,115]. Preliminary data on patients treated with VAAFT reported an 80% (8/10) success rate at median follow up of 9 months when combined with an advancement flap. Menningen et al reported success with the OTSC in 4/5 treated patients with Crohn's perianal fistulas [114]. Wilhelm et al reported a 69.2% (9/13) success rate in patients with Crohn's perianal fistula treated with FiLaC. There were no reports of any continence impairment in any of these studies. Current data for CD are sparse, so it is impossible to draw meaningful conclusions at this stage [116]. The potential benefit here lies with the minimally invasive nature of the procedures and the fact that patients may accept multiple attempts at these techniques, even with the relatively uncertain outcome, provided there is no risk to continence.

**Fecal diversion**

The challenging nature of Crohn's perianal fistula renders sustained fistula remission often unachievable, despite multiple surgical procedures combined with best medical therapy [46]. Diverting the fecal stream aims to control the inflammatory burden with concomitant medical therapy in order improve quality of life and avoid proctectomy [117,118]. Galandiuk et al [25] reported 62% (53/86) of patients with fistulizing PCD required fecal diversion at some point during their care. A systematic review reported that two-thirds of patients (from a pooled analysis of 14 studies including 373 patients) experienced a clinical response within 6 months of diversion [119]. The exact response is difficult to quantify, especially as the nature of reporting clinical response is heterogeneous in the literature and often subject to bias. Furthermore, “early fistula response” is often short-lived and clinical remission may not correlate with MRI-proven deep tissue healing [46,120,121]. The effect of temporary diversion on remission rates is modest [122,123]. Singh et al also reported in their review that restoration of continuity was attempted in 34.5% patients and only successful
Assessment of Perianal Crohn’s Disease

Clinical Assessment / MRI
EUA (consider biopsy if suspicious morphological features)
If associated fistula / abscess detected see fistula algorithm

Anal fissure
- Symptomatic
  - Supportive treatment (topical steroid/ analgesic ointments)
  - Reassurance
- Asymptomatic
  - Topical ointments (e.g. GTN, Diltiazem/ aminosalicylates)

Anal ulceration
- Topical metronidazole, Tacrolimus

Anal stenosis/stricture
- EUA / biopsy to exclude malignancy
  - Short (≤2cm)
  - Long (≥2cm)

Laxatives, topical steroids/ aminosalicylates, self (single digit) dilatation
EUA / dilatation (Hagar dilators / balloon dilatation) / interpositional flap procedures

Anal skin tag
Symptomatic
- Supportive treatment (topical steroid/ analgesic ointments)
- Reassurance
Asymptomatic
- Topical ointments (e.g. GTN, Diltiazem/ aminosalicylates)

Figure 3 Algorithm reproduced from 'Management of Perianal Crohn’s Disease in the Biologic Era', Coloproctology – A Practical Guide (Eds. Beynon, Harris, Davies, Evans) 2017 Chapter 1 (pgs 1-27), Adegbola SO, et al; Copyright Information – Springer International Publishing AG 2017, reproduced with permission of Springer

Perianal Fistula
Endoscopy to assess for proctitis
Assess luminal disease
Exclude abscess with MRI

If proctitis
- Medical management
  - Superficial / low / interphincteric fistula
    - Consider Lay - open (with caution)
  - Complex / high fistula
    - Infliximab / Adalimumab
    - Ciprofloxacin

ALGORITHM FOR MANAGEMENT OF NON-FISTULATING PERIANAL CROHN’S DISEASE

Figure 4 Algorithm reproduced from 'Management of Perianal Crohn’s Disease in the Biologic Era', Coloproctology – A Practical Guide (Eds. Beynon, Harris, Davies, Evans) 2017 Chapter 1 (pgs 1-27), Adegbola SO, et al; Copyright Information – Springer International Publishing AG 2017, reproduced with permission of Springer

Annals of Gastroenterology 31
in half. This suggests that “temporary” fecal diversion, is more often a bridge towards permanent diversion or proctectomy. The advent of biological treatment has not made a significant difference to the risk of diversion [119,124]. Successful restoration rates also remain low [119]. Studies suggest that the most important factor precluding restoration of bowel continuity is the presence of proctitis [124,125]. Other factors include multiple seton placement for fistulizing disease and other aggressive disease characteristics [124].

Temporary diversion may offer a psychological role particularly in younger patients in whom irreversible diversion (i.e., proctectomy) may be too daunting [126]. Diversion appears to have a role in improving quality of life (QoL), as demonstrated by good global QoL scores in general with patients who have undergone fecal diversion [127]. Kasparek et al [127] reported a trend toward a better quality of life with fecal diversion (using a variety of generic QoL scores) in their analysis of patients with PCD. They reported that 79% of undiverted patients complained of CD symptoms, compared to 44% in the diverted group. These questionnaires are, however, non-specific and there remains a lack of validated patient-reported outcome measures specific to perianal disease. Such scores would be able to demonstrate robustly an improvement targeted towards patients whose QoL with aggressive disease and concomitant proctitis leaves them with few therapeutic options. Fecal diversion may well trigger the dilemma of the willingness to trade the risks and consequences of permanent fecal diversion for an improved quality of life. Unfortunately, proctectomy can be complicated by poor wound healing and perineal sinus formation in up to 25-50% of patients and may necessitate plastic surgical techniques to help combat these complications [128].

Rectovaginal fistulas

CD accounts for the most common cause of rectovaginal fistulas [83] after obstetric trauma. Medical management is similar to that of perianal fistulas; however, curative surgical management options are limited. Higher fistulas and those with active proctitis or originating from a Bartholin’s abscess have a higher chance of failure [129,130]. Advancement flap procedures can be a curative option and can be performed transanally or transvaginally. Ruffolo et al [129] reviewed 11 studies that reported on flap procedures, with 224 flaps performed for rectovaginal fistulas in CD, and a comparison of transrectal and transvaginal approaches demonstrated that pooled primary closure (53% vs. 61%) and pooled overall closure (75% vs. 81%) were similar with both approaches. El-Gazzaz et al [131] evaluated long-term outcomes in 65 women with Crohn’s rectovaginal fistulas who underwent a variety of different procedures, of which the advancement flap was the most common. At a median follow up of 47 months, 46% remained healed. Multivariate analysis showed that immunomodulators were associated with successful healing (P=0.009), whereas smoking and steroids were associated with failure (P=0.04).

Concluding remarks

The management of PCD represents a challenging field in IBD. Most studies examined perianal fistula. The biologic era, despite showing major promise in IBD, has offered only limited efficacy in long-term management, particularly of fistulizing PCD. Furthermore, the literature is diluted by heterogeneity in classification, technique, and outcome measurement. The limited conclusions that can be drawn suggest that best treatment comes from combination of medical and surgical therapies [132]. The list of surgical techniques, particularly for fistula, is expanding and there is a need to evaluate these techniques with robust and uniform outcome measures [133]. Multidisciplinary management is essential [Figs. 3 and 4]. Shared management using joint clinics with gastroenterologists and surgeons could lead to better outcomes and form the basis of many national standards to ensure best practice.

References

of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. *Aliment Pharmacol Ther* 2010;32:1228-1239.


